| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
36,770,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Foghorn Therapeutics is a clinical-stage biopharmaceutical company discovering and developing medicines targeting genetically determined dependencies within the chromatin regulatory system. Co.'s product candidates are: FHD-286, which is a selective, allosteric and small-molecule, enzymatic inhibitor of BRG1 and BRM, that it is developing for the potential treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, which is a selective and intravenous, small molecule protein degrader of BRD9, a component of a form of the BAF complex that Co. is developing in clinical study in synovial sarcoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
11,000 |
11,000 |
322,297 |
322,297 |
| Total Sell Value |
$72,134 |
$72,134 |
$2,640,334 |
$2,640,334 |
| Total People Sold |
1 |
1 |
2 |
2 |
| Total Sell Transactions |
1 |
1 |
2 |
2 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Cavalie Fanny |
Chief Strategy/Bus Ops Officer |
• – – |
2024-03-11 |
4 |
S |
$6.56 |
$72,134 |
D/D |
(11,000) |
75,992 |
|
- |
|
| Gottschalk Adrian |
Chief Executive Officer |
• • – |
2023-08-17 |
4 |
GA |
$0.00 |
$0 |
I/I |
63,000 |
511,704 |
|
- |
|
| Gottschalk Adrian |
Chief Executive Officer |
• • – |
2023-08-17 |
4 |
GD |
$0.00 |
$0 |
D/D |
63,000 |
0 |
|
- |
|
| Agresta Samuel |
Chief Medical Officer |
• – – |
2023-08-16 |
4 |
S |
$8.25 |
$2,568,200 |
D/D |
(311,297) |
0 |
|
- |
|
| Agresta Samuel |
Chief Medical Officer |
• – – |
2023-08-16 |
4 |
OE |
$3.72 |
$1,158,025 |
D/D |
311,297 |
311,297 |
|
- |
|
| Gottschalk Adrian |
Chief Executive Officer |
• • – |
2023-05-26 |
4 |
GA |
$0.00 |
$0 |
I/I |
300,000 |
448,704 |
|
- |
|
| Gottschalk Adrian |
Chief Executive Officer |
• • – |
2023-05-26 |
4 |
GD |
$0.00 |
$0 |
I/I |
300,000 |
448,704 |
|
- |
|
| Gottschalk Adrian |
Chief Executive Officer |
• • – |
2023-02-17 |
4 |
A |
$0.00 |
$0 |
I/I |
184,939 |
448,704 |
|
- |
|
| Gottschalk Adrian |
Chief Executive Officer |
• • – |
2023-02-17 |
4 |
D |
$0.00 |
$0 |
I/I |
(184,939) |
448,704 |
|
- |
|
| Gottschalk Adrian |
Chief Executive Officer |
• • – |
2023-02-17 |
4 |
GA |
$0.00 |
$0 |
I/I |
4,371 |
448,704 |
|
- |
|
| Gottschalk Adrian |
Chief Executive Officer |
• • – |
2023-02-17 |
4 |
GD |
$0.00 |
$0 |
D/D |
4,371 |
63,000 |
|
- |
|
| Gottschalk Adrian |
Chief Executive Officer |
• • – |
2022-10-25 |
4 |
D |
$0.00 |
$0 |
I/I |
(4,371) |
444,333 |
|
- |
|
| Gottschalk Adrian |
Chief Executive Officer |
• • – |
2022-10-25 |
4 |
A |
$0.00 |
$0 |
D/D |
4,371 |
67,371 |
|
- |
|
| Gottschalk Adrian |
Chief Executive Officer |
• • – |
2022-09-16 |
4 |
OE |
$0.54 |
$21,600 |
D/D |
40,000 |
186,479 |
|
- |
|
| Gill Simba |
|
– • – |
2022-09-13 |
4 |
GD |
$0.00 |
$0 |
D/D |
47,939 |
34,061 |
|
- |
|
| Gill Simba |
|
– • – |
2022-09-12 |
4 |
OE |
$0.73 |
$59,860 |
D/D |
82,000 |
82,000 |
|
- |
|
| Bellon Steven F. |
Chief Scientific Officer |
• – – |
2022-08-11 |
4 |
OE |
$3.72 |
$6,912 |
D/D |
1,858 |
121,957 |
|
- |
|
| Bellon Steven F. |
Chief Scientific Officer |
• – – |
2022-05-25 |
4 |
OE |
$0.73 |
$14,320 |
D/D |
4,392 |
120,099 |
|
- |
|
| Cavalie Fanny |
Chief Strategy/Bus Ops Officer |
• – – |
2022-02-14 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
86,992 |
|
- |
|
| Gottschalk Adrian |
Chief Executive Officer |
• • – |
2022-02-10 |
4 |
GA |
$0.00 |
$0 |
I/I |
123,479 |
448,704 |
|
- |
|
| Gottschalk Adrian |
Chief Executive Officer |
• • – |
2022-02-10 |
4 |
GD |
$0.00 |
$0 |
D/D |
123,479 |
23,000 |
|
- |
|
| Bellon Steven F. |
Chief Scientific Officer |
• – – |
2022-01-10 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
50,000 |
|
- |
|
| Bellon Steven F. |
Chief Scientific Officer |
• – – |
2022-01-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
115,707 |
|
- |
|
| Kadoch Cigall |
|
– • • |
2021-12-14 |
4 |
GD |
$0.00 |
$0 |
D/D |
333,333 |
295,000 |
|
- |
|
| Decicco Carl |
Chief Scientific Officer |
• – – |
2021-12-09 |
4 |
OE |
$3.72 |
$388,033 |
D/D |
104,310 |
362,707 |
|
- |
|
40 Records found
|
|
Page 1 of 2 |
|
|
